Crossmark

The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis

Crossref DOI link: https://doi.org/10.1186/s13023-018-0874-7

Published Online: 2018-08-14

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gao, Nannan

Zhang, Tengyue

Ji, Jiadong

Xu, Kai-Feng

Tian, Xinlun https://orcid.org/0000-0003-4307-6665
Funding

Funding for this research was provided by:

State Key Project, Clinical Cohort Study of Rare Diseases. Rare Lung Disease Research Group in China (2016YFC0901502)

The Capital of the Public Health Program: Study on the Evaluation of Diagnosis and Treatment on Seven Treatable Rare Diseases (Z151100003915126)
License Information

Text and Data Mining valid from 2018-08-14
More Information

Article History

Received: 5 May 2018

Accepted: 10 July 2018

First Online: 14 August 2018

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.